Cameroon becomes first African Recipient of malaria vaccine as Nigeria anticipates turn
Cameroon achieved a milestone in the battle against malaria as it welcomed the initial shipment of Mosquirix malaria vaccines from ...
Tag: GSK
Drug prices soar as high as 1000% over GSK exit from Nigeria
Following the recent announcement of GlaxoSmithKline's (GSK) departure from the Nigerian pharmaceutical market, there has been a notable surge in ...
GSK signs £2.5 billion shingles vaccine deal with Chinese firm
GSK has signed a deal with Zhifei, China’s largest vaccine company by revenue, as the British drugmaker aims to double ...
Naira fall is responsible for rising drug prices not GSK’s exit – NAFDAC
NAFDAC has clarified that the exit of GSK pharmaceutical company is not the cause of the increase in drug prices ...
The GSK Exit: The grim realities, the abundant opportunities
Nigeria's transition triumphs amidst challenges as we enter seamlessly a fifth democratic government showing signals of resilience, despite economic and ...
GSK’s Exit from Nigerian Market: Implications for Stakeholders, Stock Market, and Economy
GSK's announcement to cease direct business operations in Nigeria reflects a significant decision with potential implications for stakeholders, the stock ...
GSK Group to cease operations in Nigeria
GSK UK Group has informed GlaxoSmithKline Consumer Nigeria PLC of its strategic intent to cease operations in Nigeria.
GSK Consumer Nigeria’s unclaimed dividend grows to N1.28 billion
The unclaimed dividend of shareholders of GlaxoSmithKline Consumer Nigeria (GSK) Plc as of December 31, 2022, grew to N1.28 billion.
GSK shareholders approve N657.73 million dividend
GlaxoSmithKline Consumer Nigeria Plc shareholders N657.73 million as dividends at the rate of 55 kobos per share.
FOREX Challenges Disrupting Drug Availability in Nigeria- GSK Nigeria
In common with many companies operating in Nigeria, foreign exchange availability continues to impact our operations.
